Literature DB >> 23516028

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.

Manabu Ogita1, Katsumi Miyauchi, Tadashi Miyazaki, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Tomotaka Dohi, Takatoshi Kasai, Takayuki Yokoyama, Shinya Okazaki, Takeshi Kurata, Hiroyuki Daida.   

Abstract

Diabetes mellitus is recognized an independent risk factor for coronary artery disease (CAD) and mortality. Clinical trials have shown that statins significantly reduce cardiovascular events in diabetic patients. However, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein cholesterol (LDL-C) levels with statin. High-density lipoprotein cholesterol (HDL-C) is an established coronary risk factor that is independent of LDL-C levels. We evaluated the impact of HDL-C on long-term mortality in diabetic patients with stable CAD who achieved optimal LDL-C. We enrolled 438 consecutive diabetic patients who were scheduled for percutaneous coronary intervention between 2004 and 2007 at our institution. We identified 165 patients who achieved target LDL-C <100 mg/dl. Patients were stratified into two groups according to HDL-C levels (low HDL-C group, baseline HDL-C <40 mg/dl; high HDL-C group, ≥40 mg/dl). Major adverse cardiac events (MACE) that included all-cause death, acute coronary syndrome, and target lesion revascularization were evaluated between the two groups. The median follow-up period was 946 days. The rate of MACE was significantly higher in diabetic patients with low-HDL-C who achieved optimal LDL-C (6.9 vs 17.9 %, log-rank P = 0.030). Multivariate Cox regression analysis showed that HDL-C is significantly associated with clinical outcomes (adjusted hazard ratio for MACE 1.33, 95 % confidence interval 1.01-1.75, P = 0.042). Low HDL-C is a residual risk factor that is significantly associated with long-term clinical outcomes among diabetic patients with stable CAD who achieve optimal LDL-C levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23516028     DOI: 10.1007/s00380-013-0330-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  41 in total

Review 1.  Isolated low HDL-cholesterol as an important risk factor for coronary heart disease.

Authors:  M Miller; P O Kwiterovich
Journal:  Eur Heart J       Date:  1990-12       Impact factor: 29.983

Review 2.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology.

Authors:  Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu
Journal:  JAMA       Date:  2009-05-27       Impact factor: 56.272

3.  Cardiovascular disease in diabetes.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2008-06       Impact factor: 19.112

4.  Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.

Authors:  U Goldbourt; S Yaari; J H Medalie
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

Review 7.  Lipid control in patients with diabetes mellitus.

Authors:  D John Betteridge
Journal:  Nat Rev Cardiol       Date:  2011-03-15       Impact factor: 32.419

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes.

Authors:  K Nasu; E Tsuchikane; O Katoh; H Fujita; J-F Surmely; M Ehara; Y Kinoshita; N Tanaka; T Matsubara; Y Asakura; K Asakura; M Terashima; T Suzuki
Journal:  Heart       Date:  2007-07-23       Impact factor: 5.994

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  13 in total

1.  Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.

Authors:  Shigemasa Tani; Atsuhiko Takahashi; Ken Nagao; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2014-07-26       Impact factor: 2.037

2.  High HDL cholesterol level after treatment with pitavastatin is an important factor for regression in carotid intima-media thickness.

Authors:  Kenji Okumura; Hideto Tsukamoto; Hideyuki Tsuboi; Haruo Hirayama; Haruo Kamiya; Masato Watarai; Ryoji Ishiki; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2014-01-24       Impact factor: 2.037

3.  Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease.

Authors:  Kenji Norimatsu; Takashi Kuwano; Shin-Ichiro Miura; Tomohiko Shimizu; Yuhei Shiga; Yasunori Suematsu; Yuiko Miyase; Sen Adachi; Ayumi Nakamura; Satoshi Imaizumi; Atsushi Iwata; Hiroaki Nishikawa; Yoshinari Uehara; Keijiro Saku
Journal:  Heart Vessels       Date:  2016-04-22       Impact factor: 2.037

4.  Serum n-3 to n-6 polyunsaturated fatty acids ratio correlates with coronary plaque vulnerability: an optical coherence tomography study.

Authors:  Takao Hasegawa; Kenichiro Otsuka; Tomokazu Iguchi; Kenji Matsumoto; Shoichi Ehara; Shinji Nakata; Satoshi Nishimura; Toru Kataoka; Kenei Shimada; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2013-09-05       Impact factor: 2.037

5.  Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset.

Authors:  Naoko Takaoka; Kenichi Tsujita; Koichi Kaikita; Seiji Hokimoto; Kenshi Yamanaga; Naohiro Komura; Tadasuke Chitose; Takamichi Ono; Michio Mizobe; Eiji Horio; Koji Sato; Naoki Nakayama; Michiyo Saito; Satomi Iwashita; Sunao Kojima; Shinji Tayama; Seigo Sugiyama; Sunao Nakamura; Hisao Ogawa
Journal:  Heart Vessels       Date:  2013-08-28       Impact factor: 2.037

6.  Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients.

Authors:  Kei Fukami; Sho-Ichi Yamagishi; Kazuko Sakai; Makoto Nasu; Seiya Okuda
Journal:  Clin Kidney J       Date:  2014-07-29

7.  Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus.

Authors:  Hyung Joon Joo; Sang-A Cho; Soon Jun Hong; Seung-Ho Hur; Jang-Ho Bae; Dong-Ju Choi; Young-Keun Ahn; Jong-Seon Park; Rak-Kyeong Choi; Donghoon Choi; Joon-Hong Kim; Kyoo-Rok Han; Hun-Sik Park; So-Yeon Choi; Jung-Han Yoon; Hyeon-Cheol Kwon; Seung-Woon Rha; Kyung-Kuk Hwang; Kyung-Tae Jung; Seok-Kyu Oh; Jae-Hwan Lee; Eun-Seok Shin; Kee-Sik Kim; Hyo-Soo Kim; Do-Sun Lim
Journal:  Lipids Health Dis       Date:  2016-11-18       Impact factor: 3.876

8.  A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.

Authors:  Seon-Ah Cha; Yong-Moon Park; Jae-Seung Yun; Tae-Seok Lim; Ki-Ho Song; Ki-Dong Yoo; Yu-Bae Ahn; Seung-Hyun Ko
Journal:  Lipids Health Dis       Date:  2017-04-13       Impact factor: 3.876

Review 9.  The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.

Authors:  Nathan K P Wong; Stephen J Nicholls; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

10.  Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography.

Authors:  Hiroko Inoue; Yuhei Shiga; Kenji Norimatsu; Kohei Tashiro; Makito Futami; Yasunori Suematsu; Makoto Sugihara; Hiroaki Nishikawa; Yousuke Katsuda; Shin-Ichiro Miura
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.